Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TC-110 T Cells · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort. |
| Phase 2 | EXPERIMENTAL | The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen. |
| Name | Type | Description |
|---|---|---|
| TC-110 T Cells | DRUG | TC-110 T Cells |
| Fludarabine | DRUG | Flu/Cy Lymphodepletion |
| Cyclophosphamide | DRUG | Flu/Cy Lymphodepletion |
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed * Patient has agreed to abide by all protocol-required procedures, including study-related assessments, and management by the treating institution for the duration of the study and LTFU * Histologically c...
TC-110 T Cells is an investigational cell therapy being studied in adults with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia. It was developed by Adaptimmune Therapeutics PLC, which trades on the Nasdaq under the ticker ADAP. The program reached Phase 1 clinical testing.
TC-110 T Cells is being studied for relapsed or refractory non-Hodgkin lymphoma in adults. The Phase 1 trial also enrolled patients with acute lymphoblastic leukemia and several lymphoma subtypes, including diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
Adaptimmune Therapeutics PLC is developing TC-110 T Cells. The company is listed on the Nasdaq under the ticker ADAP. Adaptimmune is the sponsor of the Phase 1 study evaluating the therapy in adults with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia.
TC-110 T Cells is in Phase 1 development. The single registered trial, NCT04323657, is listed as completed and enrolled 6 participants. The study was not randomized and was not double blinded, and it used a controlled design. TC-110 T Cells is investigational and has not been approved by the FDA.
TC-110 T Cells has been evaluated in one clinical trial, NCT04323657, titled TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia. The Phase 1 study enrolled 6 participants aged 18 years and older in the United States and is listed as completed.